Mineralys Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
About Mineralys Therapeutics
Pharmaceutical Preparations, SIC 2834
This biopharmaceutical company specializes in developing targeted therapies for cardiorenal metabolic conditions linked to dysregulated aldosterone. Its lead product candidate, lorundrostat, is an oral, selective aldosterone synthase inhibitor aimed at controlling conditions such as uncontrolled or resistant hypertension, chronic kidney disease, and obstructive sleep apnea. Because the candidate remains under clinical investigation and regulatory review, the enterprise currently has no approved commercial offerings, established sales segments, or direct product customers.
Operationally, the business does not operate internal manufacturing facilities and relies entirely on external contract organizations to produce raw materials and clinical supply. The provided text notes that development rights originate from a worldwide license with an Asian pharmaceutical partner and outlines clinical trials conducted across adult patient cohorts, but it specifies no facility counts, office locations, or headquarters.
Summary of the business section of Mineralys Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Mineralys Therapeutics, Inc.
- Founded
- 2019
- Headquarters
- Radnor, PA
- Address
- 150 N. Radnor Chester Road, Suite F200
- Phone
- (888) 378-6240
- Website
- mineralystx.com
- Employees
- 76, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Denver, Colorado
Stock & identifiers
- Ticker
- MLYS
- Exchange
- Nasdaq
- IPO date
- Feb 10, 2023
- Shares outstanding
- 88M, Aug 3, 2026
- Public float
- $676.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1933414
- CUSIP
- 603170101
- ISIN
- US6031701013
- EIN
- 84-1966887
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jon Congleton | Chief Executive Officer, Director | 603,621 |
| Eric Warren | Chief Commercial Officer | 45,838 |
| James J. Ferguson III | Chief Medical Officer | 102,400 |
| David Malcom Rodman | Chief Medical Officer | 51,384 |
| Adam Scott Levy | CFO and Secretary | 48,538 |
| Brian Taylor Slingsby | Director | 7,811,918 |
| Daphne Karydas | Director | 6,200 |
| Capital Healthcare Fund LP RA | Director | 1,873,429 |
| Rajeev M. Shah | Director | 5,825,521 |
| RA Capital Nexus Fund III, L.P. | Director | 4,280,051 |
| Peter Kolchinsky | Director | – |
| Ra Capital Management, L.P. | Director | 5,456,521 |
| Glenn Sblendorio | Director | 6,200 |
| Derek DiRocco | Director | 6,200 |
| Alexander M. Gold | Director | 6,200 |
| Srinivas Akkaraju | Director | 5,877,218 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 76 full-time employees, of whom 39 were primarily engaged in research and development.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 10, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 6, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |